ID

44180

Description

Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02344940

Link

https://clinicaltrials.gov/show/NCT02344940

Keywords

Versions (2)
  1. 2/8/19 2/8/19 -
  2. 9/20/21 9/20/21 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

September 20, 2021

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Breast Cancer NCT02344940

English

Eligibility Breast Cancer NCT02344940

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. women aged ≥18 years, premenopausal
Description

Gender | Age | Premenopausal state

Data type

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2]
C0001779
UMLS CUI [3]
C0232969
2. histologically confirmed invasive breast cancer by core needle biopsy, hormonal receptor positive, defined as estrogen receptor(er)/progesterone receptor(pr) positive
Description

Invasive carcinoma of breast Core needle biopsy | Hormone Receptor Positive | Estrogen receptor positive | Progesterone receptor positive

Data type

boolean

Alias
UMLS CUI [1,1]
C0853879
UMLS CUI [1,2]
C1318309
UMLS CUI [2,1]
C0019929
UMLS CUI [2,2]
C1514241
UMLS CUI [3]
C0279754
UMLS CUI [4]
C0279759
3. patients must have received standard local therapy: normalized modified radical mastectomy or breast conserving surgery with negative margin and post-surgical radiotherapy. patient should completed adjuvant therapy according to conditions, including adjuvant radiotherapy, neoadjuvant or adjuvant chemotherapy.
Description

Standard therapy | Modified radical mastectomy Normalized | Breast-Conserving Surgery | Negative Surgical Margin | Postoperative course of radiotherapy | Adjuvant therapy Completed | Radiotherapy, Adjuvant | Chemotherapy Neoadjuvant | Chemotherapy, Adjuvant

Data type

boolean

Alias
UMLS CUI [1]
C2936643
UMLS CUI [2,1]
C0024883
UMLS CUI [2,2]
C1882115
UMLS CUI [3]
C0917927
UMLS CUI [4]
C1709157
UMLS CUI [5]
C0436206
UMLS CUI [6,1]
C0677850
UMLS CUI [6,2]
C0205197
UMLS CUI [7]
C0242939
UMLS CUI [8,1]
C0392920
UMLS CUI [8,2]
C0600558
UMLS CUI [9]
C0085533
4. leukocyte ≥ 3*109/l; platelets ≥ 75*109/l; serum glutamate oxaloacetate(ast/sgot) or serum glutamic-pyruvic transaminase(alt/sgpt) <2.5 times of upper limit of normal (unl) range serum creatinine/blood urea nitrogen(bun) ≤ upper limit of normal (unl) range; written informed consent according to the local ethics committee requirements.
Description

White Blood Cell Count procedure | Platelet Count measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Creatinine measurement, serum | Blood urea nitrogen measurement | Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0023508
UMLS CUI [2]
C0032181
UMLS CUI [3]
C0201899
UMLS CUI [4]
C0201836
UMLS CUI [5]
C0201976
UMLS CUI [6]
C0005845
UMLS CUI [7]
C0021430
5. has eastern cooperative oncology group(ecog) performance score 0-2;
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. histologically confirmed hormonal receptor negative.
Description

Hormone Receptor Negative

Data type

boolean

Alias
UMLS CUI [1,1]
C0019929
UMLS CUI [1,2]
C1513916
2. have received neoadjuvant/adjuvant endocrine therapy.
Description

Hormone Therapy Neoadjuvant | Hormone Therapy Adjuvant

Data type

boolean

Alias
UMLS CUI [1,1]
C0279025
UMLS CUI [1,2]
C0600558
UMLS CUI [2,1]
C0279025
UMLS CUI [2,2]
C1522673
3. with metastatic tumor.
Description

Neoplasm Metastasis

Data type

boolean

Alias
UMLS CUI [1]
C0027627
4. family history of endometrial cancer or ovarian cancer or any other kind of gynecological malignant tumor.
Description

Family history Endometrial Carcinoma | FH: Ovarian carcinoma | Family history Gynecologic neoplasm

Data type

boolean

Alias
UMLS CUI [1,1]
C0241889
UMLS CUI [1,2]
C0476089
UMLS CUI [2]
C0559120
UMLS CUI [3]
C0006826
UMLS CUI [4,1]
C0241889
UMLS CUI [4,2]
C0017416
5. have already been detected of ovarian abnormality or endometrial thickening by transvaginal ultrasound.
Description

OVARIAN ABNORMALITY Transvaginal echography | Endometrial thickening Transvaginal echography

Data type

boolean

Alias
UMLS CUI [1,1]
C0149747
UMLS CUI [1,2]
C0203418
UMLS CUI [2,1]
C0743516
UMLS CUI [2,2]
C0203418
6. with any of complications that will increase sex hormone level: pituitary adenoma，ovarian tumor, thymic cancer，etc.
Description

Female sex hormone level Increased by Complication | Pituitary Adenoma | Ovarian neoplasm | Malignant neoplasm of thymus

Data type

boolean

Alias
UMLS CUI [1,1]
C3495860
UMLS CUI [1,2]
C0205217
UMLS CUI [1,3]
C0009566
UMLS CUI [2]
C0032000
UMLS CUI [3]
C0919267
UMLS CUI [4]
C0751552
7. with any of complications that will decrease sex hormone level:hyperthyroidism，hypothyroidism，liver cirrhosis，severe malnutrition，turner's syndrome，sex hormone synthetase deficiency, intracranial tumor, pituitary atrophy, etc.
Description

Female sex hormone level Decreased by Complication | Hyperthyroidism | Hypothyroidism | Liver Cirrhosis | Severe malnutrition | Turner Syndrome | Female sex hormones Synthetase Deficiency | Neoplasms, Intracranial | Atrophy of the pituitary

Data type

boolean

Alias
UMLS CUI [1,1]
C3495860
UMLS CUI [1,2]
C0205216
UMLS CUI [1,3]
C0009566
UMLS CUI [2]
C0020550
UMLS CUI [3]
C0020676
UMLS CUI [4]
C0023890
UMLS CUI [5]
C0311276
UMLS CUI [6]
C0041408
UMLS CUI [7,1]
C1287361
UMLS CUI [7,2]
C4522002
UMLS CUI [7,3]
C0011155
UMLS CUI [8]
C1527390
UMLS CUI [9]
C4014943
8. ovarian ablation or suppression
Description

Ovarian suppression

Data type

boolean

Alias
UMLS CUI [1]
C0677922
9. with severe non-malignant co-morbidity that will influence long-term follow up.
Description

Comorbidity Severe Influence Long-term Follow-up | Exception Malignant Neoplasms

Data type

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0205082
UMLS CUI [1,3]
C4054723
UMLS CUI [1,4]
C1517942
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0006826
10. with severe hepatic dysfunction, child-pugh c.
Description

Liver Dysfunction Severe Child-Pugh Classification

Data type

boolean

Alias
UMLS CUI [1,1]
C0086565
UMLS CUI [1,2]
C0205082
UMLS CUI [1,3]
C4050412
11. with severe cardiac dysfunction, new york heart association (nyha) grading iii or worse.
Description

Cardiac dysfunction Severe New York Heart Association Classification

Data type

boolean

Alias
UMLS CUI [1,1]
C3277906
UMLS CUI [1,2]
C0205082
UMLS CUI [1,3]
C1275491
12. known severe hypersensitivity to any drugs in this study;
Description

Severe allergy Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1,1]
C2945656
UMLS CUI [1,2]
C0013230
Back to the top of the page

Similar models

Eligibility Breast Cancer NCT02344940

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Gender | Age | Premenopausal state
Item
1. women aged ≥18 years, premenopausal
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0232969 (UMLS CUI [3])
Invasive carcinoma of breast Core needle biopsy | Hormone Receptor Positive | Estrogen receptor positive | Progesterone receptor positive
Item
2. histologically confirmed invasive breast cancer by core needle biopsy, hormonal receptor positive, defined as estrogen receptor(er)/progesterone receptor(pr) positive
boolean
C0853879 (UMLS CUI [1,1])
C1318309 (UMLS CUI [1,2])
C0019929 (UMLS CUI [2,1])
C1514241 (UMLS CUI [2,2])
C0279754 (UMLS CUI [3])
C0279759 (UMLS CUI [4])
Standard therapy | Modified radical mastectomy Normalized | Breast-Conserving Surgery | Negative Surgical Margin | Postoperative course of radiotherapy | Adjuvant therapy Completed | Radiotherapy, Adjuvant | Chemotherapy Neoadjuvant | Chemotherapy, Adjuvant
Item
3. patients must have received standard local therapy: normalized modified radical mastectomy or breast conserving surgery with negative margin and post-surgical radiotherapy. patient should completed adjuvant therapy according to conditions, including adjuvant radiotherapy, neoadjuvant or adjuvant chemotherapy.
boolean
C2936643 (UMLS CUI [1])
C0024883 (UMLS CUI [2,1])
C1882115 (UMLS CUI [2,2])
C0917927 (UMLS CUI [3])
C1709157 (UMLS CUI [4])
C0436206 (UMLS CUI [5])
C0677850 (UMLS CUI [6,1])
C0205197 (UMLS CUI [6,2])
C0242939 (UMLS CUI [7])
C0392920 (UMLS CUI [8,1])
C0600558 (UMLS CUI [8,2])
C0085533 (UMLS CUI [9])
White Blood Cell Count procedure | Platelet Count measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Creatinine measurement, serum | Blood urea nitrogen measurement | Informed Consent
Item
4. leukocyte ≥ 3*109/l; platelets ≥ 75*109/l; serum glutamate oxaloacetate(ast/sgot) or serum glutamic-pyruvic transaminase(alt/sgpt) <2.5 times of upper limit of normal (unl) range serum creatinine/blood urea nitrogen(bun) ≤ upper limit of normal (unl) range; written informed consent according to the local ethics committee requirements.
boolean
C0023508 (UMLS CUI [1])
C0032181 (UMLS CUI [2])
C0201899 (UMLS CUI [3])
C0201836 (UMLS CUI [4])
C0201976 (UMLS CUI [5])
C0005845 (UMLS CUI [6])
C0021430 (UMLS CUI [7])
ECOG performance status
Item
5. has eastern cooperative oncology group(ecog) performance score 0-2;
boolean
C1520224 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Hormone Receptor Negative
Item
1. histologically confirmed hormonal receptor negative.
boolean
C0019929 (UMLS CUI [1,1])
C1513916 (UMLS CUI [1,2])
Hormone Therapy Neoadjuvant | Hormone Therapy Adjuvant
Item
2. have received neoadjuvant/adjuvant endocrine therapy.
boolean
C0279025 (UMLS CUI [1,1])
C0600558 (UMLS CUI [1,2])
C0279025 (UMLS CUI [2,1])
C1522673 (UMLS CUI [2,2])
Neoplasm Metastasis
Item
3. with metastatic tumor.
boolean
C0027627 (UMLS CUI [1])
Family history Endometrial Carcinoma | FH: Ovarian carcinoma | Family history Gynecologic neoplasm
Item
4. family history of endometrial cancer or ovarian cancer or any other kind of gynecological malignant tumor.
boolean
C0241889 (UMLS CUI [1,1])
C0476089 (UMLS CUI [1,2])
C0559120 (UMLS CUI [2])
C0006826 (UMLS CUI [3])
C0241889 (UMLS CUI [4,1])
C0017416 (UMLS CUI [4,2])
OVARIAN ABNORMALITY Transvaginal echography | Endometrial thickening Transvaginal echography
Item
5. have already been detected of ovarian abnormality or endometrial thickening by transvaginal ultrasound.
boolean
C0149747 (UMLS CUI [1,1])
C0203418 (UMLS CUI [1,2])
C0743516 (UMLS CUI [2,1])
C0203418 (UMLS CUI [2,2])
Female sex hormone level Increased by Complication | Pituitary Adenoma | Ovarian neoplasm | Malignant neoplasm of thymus
Item
6. with any of complications that will increase sex hormone level: pituitary adenoma，ovarian tumor, thymic cancer，etc.
boolean
C3495860 (UMLS CUI [1,1])
C0205217 (UMLS CUI [1,2])
C0009566 (UMLS CUI [1,3])
C0032000 (UMLS CUI [2])
C0919267 (UMLS CUI [3])
C0751552 (UMLS CUI [4])
Female sex hormone level Decreased by Complication | Hyperthyroidism | Hypothyroidism | Liver Cirrhosis | Severe malnutrition | Turner Syndrome | Female sex hormones Synthetase Deficiency | Neoplasms, Intracranial | Atrophy of the pituitary
Item
7. with any of complications that will decrease sex hormone level:hyperthyroidism，hypothyroidism，liver cirrhosis，severe malnutrition，turner's syndrome，sex hormone synthetase deficiency, intracranial tumor, pituitary atrophy, etc.
boolean
C3495860 (UMLS CUI [1,1])
C0205216 (UMLS CUI [1,2])
C0009566 (UMLS CUI [1,3])
C0020550 (UMLS CUI [2])
C0020676 (UMLS CUI [3])
C0023890 (UMLS CUI [4])
C0311276 (UMLS CUI [5])
C0041408 (UMLS CUI [6])
C1287361 (UMLS CUI [7,1])
C4522002 (UMLS CUI [7,2])
C0011155 (UMLS CUI [7,3])
C1527390 (UMLS CUI [8])
C4014943 (UMLS CUI [9])
Ovarian suppression
Item
8. ovarian ablation or suppression
boolean
C0677922 (UMLS CUI [1])
Comorbidity Severe Influence Long-term Follow-up | Exception Malignant Neoplasms
Item
9. with severe non-malignant co-morbidity that will influence long-term follow up.
boolean
C0009488 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C4054723 (UMLS CUI [1,3])
C1517942 (UMLS CUI [1,4])
C1705847 (UMLS CUI [2,1])
C0006826 (UMLS CUI [2,2])
Liver Dysfunction Severe Child-Pugh Classification
Item
10. with severe hepatic dysfunction, child-pugh c.
boolean
C0086565 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C4050412 (UMLS CUI [1,3])
Cardiac dysfunction Severe New York Heart Association Classification
Item
11. with severe cardiac dysfunction, new york heart association (nyha) grading iii or worse.
boolean
C3277906 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C1275491 (UMLS CUI [1,3])
Severe allergy Investigational New Drugs
Item
12. known severe hypersensitivity to any drugs in this study;
boolean
C2945656 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial